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ABSTRACT 
Aims 
The concept of using specific dietary components to selectively modulate the gut 
microbiota to confer a health benefit, defined as prebiotics, originated in 1995. In 2018, 
a group of scientists met at the International Scientific Association for Probiotics and 
Prebiotics annual meeting in Singapore to discuss advances in the prebiotic field, 
focussing on issues affecting functionality, research methodology, and geographical 
differences. 
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Methods and Results 
The discussion ranged from examining scientific literature supporting the efficacy of 
established prebiotics, to the prospects for establishing health benefits associated with 
novel compounds, isolated from different sources.  
Conclusions 
While many promising candidate prebiotics from across the globe have been 
highlighted in preliminary research, there are a limited number with both 
demonstrated mechanism of action and defined health benefits as required to meet the 
prebiotic definition. 
Prebiotics are part of a food industry with increasing market sales, yet there are great 
disparities in regulations in different countries. Identification and commercialisation of 
new prebiotics with unique health benefits means that regulation must improve and 
remain up-to-date so as not to risk stifling research with potential health benefits for 
humans and other animals. 
Significance and Impact of Study  
This summary of the workshop discussions indicates potential avenues for expanding the 
range of prebiotic substrates, delivery methods to enhance health benefits for the end 
consumer, and guidance to better elucidate their activities in human studies. 
 
Keywords: Prebiotics, ISAPP, gut fermentation, microbiome, health benefits 
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Introduction  
Prebiotic discovery and definitions 
Prebiotics were originally instigated as dietary means of altering the human colonic 
microbiota towards a more favourable community structure (Gibson and Roberfoid 
1995). Initially, most studies focussed upon inulin type fructans that exerted selective 
stimulation of gut bacterial genera, notably bifidobacteria, after a short feeding period. 
This occurred in a variety of human intervention studies (Roberfroid et al. 2010), at 
doses ranging from 4-30g/day in adults. At that stage, any dietary material that entered 
the large intestine was considered a candidate prebiotic. This included carbohydrates 
such as resistant starch and dietary fibre as well as proteins and lipids. More than 20 
years on, recognised prebiotics (definition Box 1; Table 1) remain mostly confined to 
non-digestible oligosaccharides, some of which confer the degree of fermentation 
selectivity that is required to support beneficial intestinal microbes. Oligosaccharides 
are carbohydrates consisting of between approximately 2 and 10 saccharide units while 
polysaccharides consist of 10 or more saccharide units. Oligosaccharides occur 
naturally in several foods but can also be commercially produced through the 
hydrolysis of polysaccharides (e.g. dietary fibres, starch) or through catabolic enzymatic 
reactions from lower molecular weight sugars. 
 
 In 2004, the concept of prebiotics was expanded to encompass beneficial effects 
on all aspects of the gastrointestinal tract, not just the colon (Gibson et al. 2004) with 
three criteria being required for a substance to be defined as a prebiotic: 
• resist gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal 
absorption 
• fermentation by intestinal microbiota, and  
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 selectively stimulate the growth and/or activity of intestinal bacteria associated 
with health and well-being 
 In 2017, International Scientific Association for Probiotics and Prebiotics (ISAPP) 
published a consensus view on prebiotics refining the definition to “a substrate that is 
selectively utilised by host microorganisms conferring a health benefit” (Gibson et al. 
2017). The main points within this refinement were that the microbes responding to 
prebiotics should be health promoting bacteria, without specifying which. Moreover, 
the site of effect could be any mixed microbial community associated with humans or 
animals (not limited to the gastrointestinal system), but those effects need to be 
confirmed in vivo with the target host. The gastrointestinal tract (GIT) runs from the 
oral cavity to the rectum, however previous definitions, and subsequent research, 
focussed on the lower parts of the GIT. The new definition deliberately avoids specifying 
the intestine, opening up other targets containing a mixed microbiome, such as the 
urogenital tract, skin and the upper GIT including the mouth. Another point was that 
prebiotics require selective metabolism by live host microorganisms to improve or 
restore host health. This brings into play the importance of assessing microbial function 
as well as composition, in combination with appropriately validated health biomarkers.  
 
Current prebiotics and candidate prebiotics 
In order to fully classify a substance as a prebiotic, reproducible randomised controlled 
studies establishing direct links between the prebiotic and health are needed in the 
specific target host. Some candidate prebiotics lack data confirming that the compound 
confers a health benefit in humans (Table 1). However, compounds that do not act as 
prebiotics for humans may be effective prebiotics for animals. 
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 Non-digestible carbohydrates that are confirmed prebiotics, meeting the above 
criteria and which have proven effects in human studies are fructans and galactans. 
Inulin-type fructans (ITF) contain a terminal glucose residue with a β-linkage to a chain 
of β-linked fructose residues in the form Glu α1-2[β fru 2-1]n. Individual ITF are 
distinguished by their degree of polymerization (DP - the number of monomers in the 
chain), with the number of fructose units ranging from 2 to 70. Short-chain ITF, known 
as oligofructose or fructo-oligosaccharide (FOS) generally have a DP less than 10. ITF of 
all chain lengths are important prebiotic substrates with well documented effects on 
intestinal bifidobacteria. Most bifidobacteria break down and utilize FOS due to 
possession of a competitive β-fructofuranosidase enzyme (Imamura et al. 1994), 
expressed at high levels by bifidobacteria in mixed culture.  
Galactans, or galacto-oligosaccharides (GOS) are galactose-containing 
oligosaccharides of the form Glu α1-4[β Gal 1-6]n where n ranges from 2 to 10, and are 
produced from lactose syrup using the transgalactosylase activity of the β-galactosidase 
enzyme. This can be sourced from several microorganisms such as yeast, bacilli, 
bifidobacteria and lactobacilli. 
 
Sources of prebiotics 
Established and novel plant food sources of prebiotics 
Compounds with prebiotic activity occur naturally in many whole foods, including leek, 
asparagus, garlic, onion, wheat and bananas (van Loo et al. 1995) (Table 1). ITF can be 
extracted from several food crops, mainly root vegetables and tubers, e.g. chicory root 
and Jerusalem artichoke. Other carbohydrate components in plants with prebiotic 
potential include polysaccharides in plant cell walls, e.g. xylans, pectins. These 
components are gaining popularity as candidate prebiotics due to their indigestibility in 
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the upper gastrointestinal tract and fermentation by the colonic microbiota. Plants that 
have been reported as good sources of indigestible carbohydrates, with possible 
prebiotic properties include dandelion green, dahlia tuber, garlic, shallot, yacon, okra, 
gourd-type vegetables, mushrooms and barley. Legumes are rich in dietary fibre, some 
of which have potential as prebiotics. Lupin and chickpea kernel fibre stimulates colonic 
bifidobacterial growth and contributes to colon health while chickpea grains are a good 
source of α-galacto-oligosaccharide (Table 1) (Smith et al. 2006). 
Most plants with investigated prebiotic potential are of western origin, and it is 
important to explore other parts of the world, particularly the Asian region, as a source 
of novel prebiotics. Asia is the largest and most populous continent on earth, with 
extremely diverse biological resources. One interesting source is sago starch, from palm 
(Metroxylon sagu) indigenous to South-East Asia. In its native form it is called lemantak 
and contains about 60% resistant starch (Arshad et al. 2018). In vitro and in vivo studies 
have demonstrated the ability of sago starch to increase numbers of Lactobacillus and 
Bifidobacterium spp. (Arshad et al. 2018). Studies on the effects of resistant starch on 
glycemic index, insulin responses, and satiety clearly demonstrate its role as a 
functional food (Zaman and Sarbini 2016). Another potential ‘prebiotic crop’ 
abundantly grown in Asia, particularly India, is lentils. The non-digestible carbohydrate 
content of lentils is approximately 13% (Johnson et al. 2013). 
In addition to terrestrial plants, aquatic sources such as seaweeds are cultivated 
in East Asia and South-East Asia for carrageenan. The complex structure of this 
polysaccharide makes it resistant to mammalian enzymatic degradation, however it is 
fermented by the colonic microbiota. The red seaweed (Kappaphycus alvarezii) led to 
significant increase of Bifidobacterium spp. numbers and acetate and propionate 
concentrations during in vitro fermentations (Bajury et al. 2017). It will be interesting to 
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establish the potential of these plants as emerging and novel prebiotic ingredients. 
Human studies demonstrating in vivo activity and conferred health benefit are obvious 
next steps. 
Specific plants can be used both as sources of prebiotic compounds and added to 
the diet as whole foods with potential prebiotic effects monitored. Kiwifruit are a rich 
source of soluble and insoluble fibre, composed of pectic polysaccharides, cellulose and 
hemicellulose (Carnachan et al. 2012; Sims et al. 2013). A number of in vitro and in vivo 
studies (Han et al. 2011; Paturi et al. 2014; Blatchford et al. 2015) have investigated the 
ability of whole, fresh kiwifruit to modulate the colonic microbiota and the generation 
of metabolites such as short-chain fatty acids (SCFA). Although such changes in SCFA or 
microbial populations have not been directly linked to a health benefit, they can suggest 
shifts in gastrointestinal function that may indirectly impact physiological processes.  
A human intervention trial with green kiwifruit in Italian participants with 
Irritable Bowel Syndrome constipation type (IBS-C) assessed the effect on the 
composition of the faecal microbiota. After intervention, kiwifruit significantly reduced 
Clostridiaceae and Streptococcaceae in patients with IBS-C, while both kiwifruit and 
psyllium significantly increased the levels of Lachnospiraceae in patients with IBS-C 
(Cremon et al. 2018). These findings showed that kiwi fruit consumption could alter 
microbial composition, however, direct evidence of any improved health outcome 
remains outstanding. 
Whole foods such as kiwifruit can also contain non-carbohydrate compounds 
which may act synergistically with other prebiotic compounds present in the food. SCFA 
production is often attributed exclusively to the fermentation of dietary fibre and 
prebiotics. However, an in vitro study using a simulated intestinal ecosystem found that 
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SCFA production correlated with both the total fibre content and a range of 
polyphenolic compounds present in kiwifruit (Parkar et al. 2017).  
Cereal plants such as oats and barley contain β-glucan, a water-soluble non-
starch polysaccharide that is found mainly on the bran and concentrated in the aleurone 
and subaleurone layers. β-glucan in cereal plants is a linear polymer comprised of D-
glucose joined by β-(1,3;1,4)-glycosidic bonds, that imparts resistance to digestion in 
the upper GI tract of mammals. Consequently, it is fermented in the large intestine by 
the gut microbiota. Oats comprise 3-8% β-glucan, of which approximately 80% is 
water-soluble. Barley comprises 2-20% β-glucan, with a lower water-soluble fraction 
(65%) compared to oats (El Khoury et al. 2012). A high level of solubility renders oat 
bran an excellent source of β-glucan for gut bacterial fermentation. In vitro and in vivo 
studies showed that oat β-glucan could selectively stimulate the growth of lactobacilli 
and bifidobacteria, leading to the production of acetic and lactic acids 
(Charalampopoulos et al. 2002). These characteristics qualify oats as a candidate 
prebiotic. Much of the research, to date, has concentrated on yeast or fungi-derived β-
glucan that modulate the immune system. Further investigations into the activity of 
cereal β-glucans in human studies are needed to establish their prebiotic potential. 
Selection of ‘nutritious’ cereal and other foods crops through specific breeding 
and understanding of environmental and genetic factors affecting prebiotic 
carbohydrate content is of importance (Johnson et al. 2013). These may allow improved 
selection of prebiotic crops for mass production. A study on wheat grain demonstrated 
that certain cultivars had high levels of grain fructan, with advanced lines containing > 
2% (Huynh et al. 2008). There are also huge differences in dietary fibres between 
modern and ancient durum wheat cultivars (Marotti et al. 2012). In vitro research 
further demonstrated that the soluble dietary fibre from ancient durum wheat 
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selectively proliferated microbial growth of Bifidobacterium pseudocatenulatum B7003 
and Lactobacillus plantarum L12 strains (Marotti et al. 2012). Enhanced breeds of sweet 
wheat had about 7 times higher concentration of soluble dietary fibre i.e. fructan, in 
comparison to wild-type lines (Nakamura et al. 2006). Oat and barley cultivars are 
being bred with increased β-glucan content to reduce the amount required to achieve a 
cholesterol lowering effect.  
 
Non-carbohydrate prebiotic components in plants  
Currently, most accepted prebiotics are carbohydrates that bacteria utilise for growth, 
with direct or indirect effects on host health. However, as observed with kiwifruit, other 
compounds present in plants may also be metabolised by bacteria, releasing 
components that may be beneficial for health and thus ‘fit’ the current definition of 
prebiotics 
Dietary polyphenols are natural compounds occurring in plants; available in 
fruits, vegetables, cereals, tea, coffee and wine. Most polyphenols are of low 
bioavailability, and their influence on health may be either through intestinal 
absorption or interaction with colonic microbiota, depending on their structural 
complexity and polymerisation. About 5 to 10% of total polyphenol intake is absorbed 
in the small intestine (i.e. low-molecular-weight polyphenols, the monomeric and 
dimeric structures). The remaining polyphenols (oligomeric and polymeric 
polyphenols) may accumulate in the large intestine where they are subject to enzymatic 
activities of the gut microbiota (Cardona et al. 2013). 
The Asian region offers plentiful polyphenol-rich herbs and spices that have 
been used as traditional medicines since ancient times. A study observed increased 
Bacteroidetes compared to Firmicutes through use of polyphenols from black tea 
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(Camellia sinensis) in simulated intestinal microbial ecosystems (Kemperman et al. 
2013). Turmeric root (Curcuma longa) is widely used as condiment in Asian food as well 
as a traditional remedy in Chinese and Indian Ayurvedic medicine. Curcuminoids are 
metabolised by colonic microbiota, modulating bacterial populations and their 
metabolic activity (Lu et al. 2017). The black pepper (Piper nigrum L.) is well-known for 
the presence of high bioactive compounds e.g. piperine that are anti-inflammatory, anti-
oxidants and anti-bacterial, as well as containing up to 40% dietary fibre, making the 
species an interesting prebiotic candidate (Lu et al. 2017). 
Components of the gut microbiota such as Escherichia coli, Bifidobacterium spp., 
Lactobacillus spp., Bacteroides spp., Eubacterium spp. may catalyse the metabolism of 
phenolics into lower molecular weight phenolic metabolites that may exert health 
effects on the host (Duncan et al. 2016). Attributed health properties include protection 
against gastrointestinal disorders, nutrient processing, reduction of serum cholesterol, 
reinforcement of intestinal epithelial cell-tight junctions, and modulation of the 
intestinal immune response through cytokine stimulation (Cardona et al. 2013). 
However, the effect of dietary polyphenols on modulation of the gut environment and 
its underlying mechanisms is poorly understood, thus more research is needed, 
particularly in vivo. 
 
Delivery of prebiotics  
Incorporation of prebiotics into functional foods 
Due to the dose of prebiotic required to exert an effect on health, it is not always 
feasible for an oligosaccharide to exert a profound prebiotic effect through elevated 
ingestion of whole foods. Another possible route towards success is the fortification of 
more frequently consumed foods – which is the premise of functional foods. Functional 
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foods provide health benefits beyond the nutritive value of the food. Many definitions of 
‘functional food’ have been proposed by various entities such as International Food 
Information Council (IFIC), International Life Sciences Institute (ILSI), Health Canada 
and Nutrition Business Journal. However, the general consensus definition is “a food or 
dietary component that can exert health benefits and/or disease prevention, beyond 
basic nutritional needs”. Functional foods affect various specific functions in the body 
due to active ingredients that are naturally present or added to the food, e.g. vitamins 
and minerals, cholesterol lowering ingredients, fibres, antioxidant properties, beneficial 
microbes and prebiotics. Prebiotic-containing functional foods can take many dietary 
forms including yogurts, cereals, bread, biscuits, energy bars, milk desserts, ice-creams, 
spreads, infant formulae and others.  
Effect of food incorporation on prebiotic activity 
It is relevant to address whether functionality of the prebiotic is affected by the final 
food matrix, particularly since research determining prebiotic activity is often carried 
out on a prebiotic in a powdered form. 
During research on the beneficial effects of prebiotics for cardiometabolic health, 
galactoligosaccharides (B-GOS) as a powdered supplement, resulted in significant 
increases in bifidobacteria and reduction in some Gram-negative genera, in a cohort of 
45 overweight adults. These changes were concomitant with reduced markers of 
metabolic syndrome and decreased insulin, total cholesterol, triacylglycerides (TAGs), 
and the total cholesterol to high density lipoprotein (HDL) ratio. It was concluded from 
this study that prebiotic-induced changes in the gut microbiota contributed to the 
positive outcomes observed (Vulevic et al. 2013). 
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Subsequently two double–blind, placebo-controlled, randomised cross-over 
studies utilised B-GOS incorporated into functional foods- B-GOS enriched orange juice 
and bread. Effects on the faecal microbiota and on markers of metabolic syndrome and 
associated inflammation were investigated. The interventions enrolled 29 volunteers 
and 30 volunteers on juice and bread respectively, at the same doses used in the 
previous supplement trial. The final products were well tolerated by sensory taste 
panels and their prebiotic effects confirmed using an in vitro gut model system 
(Costabile et al. 2015a, 2015b). Results of the intervention demonstrated that neither 
the enriched orange juice or bread products elicited the range of benefits seen with the 
powdered prebiotic, although the bread showed some potential to modulate the 
inflammatory response. The pro-inflammatory IL-6 increased following consumption of 
placebo breads over 12 weeks, but this effect was negated by B-GOS bread. As not all 
volunteers on the study had dyslipidaemia, or raised insulin levels, a modification was 
not always apparent. However, by stratifying the volunteers, and grouping those with 
starting triglyceride levels of over 1mmol/l, the prebiotic in the juice study did reduce 
this. Major modifications in other lipid levels and blood sugar levels were not observed. 
There are a number of potential explanations for the observed differences, some 
of which relate to the study product itself. In the production of functional foods, 
additional manufacturing processes such as heating, spray-drying and freeze-drying 
may affect the structure and influence availability of the prebiotic. Once functional foods 
are produced, transportation and storage may also affect prebiotic composition, where 
fluctuations of temperature and moisture can be a concern. Preparation of prebiotic-
containing foods in the home, such as cooking, may also influence bioavailability or 
function in the host. Furthermore, other fermentable components present (such as 
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pectin, starches, xylans) could potentially compete with or otherwise influence 
microbiome fermentation.  
It is essential to consider all of these factors when assessing the prebiotic status 
of foods available to consumers and highlight the importance of complete testing of the 
finished product, to confirm prebiotic activity.  
Beyond intrinsic efficacy of a prebiotic product, other factors influence the 
optimal choice of prebiotic format for any given individual, be it whole foods, functional 
foods, or supplements (Figure 1). For any given individual, one type of delivery form 
may be preferred depending on factors such as convenience, cost, dietary and food 
preparation habits and preferences, palatability, health knowledge around the role of 
prebiotics, and values and cultural practices surrounding food and supplementation. 
Perceptions of palatability and convenience may vary significantly between individuals 
and will influence the degree to which they can maintain the intervention, in both the 
short and long term. When foods are used to deliver prebiotics, daily dosage may be 
more variable due to dietary fluctuations, although the impact of this on long term 
interventions is currently unknown.  
The importance of individual preferences in the acceptance and implementation 
of therapeutic interventions with prebiotics cannot be discarded when assessing 
optimal methods for delivery, as these, along with the intrinsic qualities of the therapy, 
will be what ultimately determines successful health outcomes.  
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Understanding prebiotic mechanisms – towards effective characterisation and 
measurement 
Therapeutic effects of prebiotics 
There is now strong evidence that the composition of the gut microbiota is altered in 
many diseases, including inflammatory bowel disease (IBD), obesity and irritable bowel 
syndrome (IBS). Importantly, the intestinal microbial population is accessible to dietary 
and therapeutic intervention and thus represents an exciting target for the prevention 
and treatment of many disorders.  
In accordance with this, the health potential of prebiotics are wide-reaching, 
currently including (Gibson et al. 2017) the gastrointestinal tract (e.g. inhibition of 
pathogens, immune stimulation), cardiometabolism (e.g. reduction in blood lipid levels, 
effects upon insulin resistance), mental health (e.g. production of metabolites that 
influence brain function, energy and cognition) and bone (e.g. mineral bioavailability) 
(Figure 2). These health effects are mediated by a variety of mechanisms, including 
changes in microbiome composition and levels of microbial metabolites, including short 
chain fatty acids. 
 
Impacts on the microbiome – in vitro and in vivo 
Increased knowledge into the composition of the gut microbiota in the last 20 years has 
shown that the original targets of prebiotics (bifidobacteria and lactobacilli) are minor 
components of the gut microbiota, which is dominated by Bacteroidetes and Firmicutes, 
including Lachnospiraceae and Ruminococcaceae. Prebiotics also change metabolic 
output, specifically increasing butyrate concentrations (Riviere et al. 2016), yet neither 
bifidobacteria nor lactobacilli produce butyrate. It is now known that ITF not only 
stimulate bifidobacterial numbers, but can also result in increased numbers of 
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Faecalibacterium prausnitzii (Ramirez-Farias et al. 2009) while high molecular weight 
arabinoxylans stimulated Roseburia species (Neyrinck et al. 2011). F. prausnitzii and 
Roseburia spp. are among the most abundant butyrate producers in the human gut 
(Louis et al. 2010).  
Studies in pure culture have confirmed the ability of various bacterial genera to 
utilise prebiotics as growth substrates (Scott et al. 2014). In fact, several researchers 
have shown that the more complex ITF are utilised more effectively by other bacteria in 
monoculture than they are by bifidobacteria (reviewed in De Vuyst and Leroy 2011). 
However, effects in monoculture may not translate to effects in vivo as other factors can 
impact on the ability for prebiotics to support beneficial changes. For example, different 
individuals tend to be colonised by different specific species of bifidobacteria, and 
within the Bifidobacterium genus there is considerable variation in the ability of 
different species to utilise different chain lengths of ITF (Selak et al. 2016). Therefore, 
individual variation in bifidobacterial species colonisation has an important impact on 
the potential effects of prebiotics, which may help explain why there may be responders 
and non-responders within studies. In a study involving 18 subjects consuming 
different doses of GOS daily, bifidobacterial population only increased in nine 
individuals, the responders (Davis et al. 2010). Clearly, if the original bacterial 
population does not contain the specific bacterium capable of utilising the added 
prebiotic substrate, the population cannot increase. 
Another important consideration is that gut bacteria exist in a competitive, 
mixed ecosystem, meaning that data from pure culture experiments does not translate 
into an ability to utilise the same substrate in a competitive environment. Bacterial 
cross-feeding is also an important consideration in determining which bacteria can be 
stimulated by prebiotics. In a competitive environment, some bacteria are efficient 
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scavengers of oligo- and mono-saccharides released following degradation of longer 
chain molecules by other members of the microbiota. Other bacteria rely on metabolites 
released by primary degraders for growth. This has been demonstrated effectively in 
co-culture. Bifidobacterium adolescentis grew very efficiently on FOS, releasing lactate, 
and acetate, while Eubacterium hallii was unable to grow on the FOS substrate. 
However, in mixed culture, growth of both bacteria was confirmed by Q-PCR 
quantification, and butyrate but no lactate was detected in the medium (Belenguer et al. 
2006; Moens et al. 2017). Co-culture experiments between Faecalibacterium prausnitzii 
and four different Bifidobacterium species showed that cross-feeding interactions could 
be competitive or mutually beneficial, depending on the species involved (Moens et al. 
2016). Co-culture experiments of Bifidobacterium longum and Eubacterium rectale on 
arabinoxylan oligosaccharides illustrated that butyrate production relied on the 
conversion of B. longum acetate by E. rectale (Riviere et al. 2015). Studies in which 
labelled isotope was added to faecal batch cultures demonstrated that 80% of butyrate 
production relied on interconversion of acetate and lactate to butyrate (Morrison et al. 
2006). These experiments clearly show that cross-feeding by other members of the 
commensal microbiota on the acetate and lactate produced by the primary oligofructose 
degrader, the Bifidobacterium, result in butyrate production – another answer to the 
prebiotic conundrum. 
Ultimately, in order to be classified as a prebiotic, an alteration in microbial 
function and/or composition leading to a health benefit has to be demonstrated in the 
final host. Since prebiotic intervention studies often uncover responders and non/mild-
responders in the study population, it may be useful to be able to pre-categorise 
individuals based on starting microbial populations, thus enabling predictions as to 
whether or not an intervention may have an effect. However, this is not easy. Although 
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there are now many methods to enumerate bacteria in faecal samples, there remains 
some debate as to how valid these are to represent bacterial numbers higher up the gut. 
This is important with respect to the activities of prebiotics which exert their function 
in the proximal colon. Additionally, many bacterial enumerations have a detection 
threshold of 104 -105 cells /g faeces. It is thus difficult to differentiate between bacteria 
that are absent, and those below the levels of detection. A bacterium present, but 
undetectable, could be stimulated to detectable levels on delivery of the appropriate 
growth substrate.   
 
Effects mediated by short chain fatty acids 
Bacterial fermentation of dietary fibre, including prebiotics, in the large intestine results 
in the production of short chain fatty acids (SCFA). SCFA have been associated with a 
number of beneficial effects in the gastrointestinal tract (GIT), including intestinal tissue 
proliferation, enhanced absorption of minerals and water, modulation of GIT 
contractility, increased numbers of beneficial bacteria and reduced numbers of 
pathogenic bacteria. Specific SCFA are the main energy source for epithelial cells and 
can also play a role in appetite control and regulating host metabolism through their 
cognate receptors GPR41/FFAR-3 and GPR43/FFAR-2 (den Besten et al. 2013; 
Chambers et al. 2015). Thus, increased production of SCFA may be an important 
mechanism by which prebiotics can contribute to health. 
SCFA produced by bacterial fermentation are mainly acetate, propionate, and 
butyrate. Butyrate is utilised directly by the colonocytes for energy (Roediger et al. 
1982) whereas acetate and propionate are absorbed and transported systemically 
through the hepatic portal vein.  
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In the liver, propionate participation in gluconeogenesis is established 
(Cummings et al. 1995). However, studies on its hypocholesterolemic effects are 
contradictory. In vitro studies on hepatocytes demonstrated that propionate inhibited 
cholesterol synthesis from acetyl-CoA through inhibition of the rate-limiting enzyme 
HMG-CoA reductase (Wright et al. 1990). In vivo studies on rats and pigs showed that 
ingestion of cereal-based, water-soluble non-starch polysaccharides increased 
propionate concentration in the hepatic portal blood along with a lowered plasma and 
hepatic level of cholesterol (Illman et al. 1988; de Smet et al. 1988). Despite cholesterol-
lowering effects, an increase in the rate of cholesterol synthesis was also observed in 
these studies. Nevertheless, a human study with a rectal infusion of acetate and 
propionate showed that the latter inhibited synthesis of cholesterol from acetate 
(Wolever et al. 1991). These differences could be partly due to variations in dose, 
methods of administration, and  source of fermentable carbohydrate. 
In contrast, acetate in the liver serves as a substrate for ATP production as well 
as for long-chain fatty acid and cholesterol synthesis. Reported effects of acetate on lipid 
metabolism include significantly decreased serum levels of free fatty acids due to a 
reduction in their synthesis and an increase in oxidation (Wolever et al. 1991). The 
hypothetical mechanism is that acetate induces phosphorylation of AMP-activated 
protein kinase by increasing the AMP/ATP ratio, which leads to the upregulation of 
PGC-1, a PPAR-coactivator that regulates transcription factors related to cholesterol, 
lipid and glucose metabolism (Ge et al. 2008). Such an effect is also exerted indirectly by 
the SCFA-FFAR2 signalling pathway in white adipose tissue. Activation of FFAR2 by 
SCFA boosts leptin production where it is transported to the liver and exerts regulatory 
effects on lipid metabolism through the same pathway as SCFA (Minokoshi et al. 2002).  
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Butyrate and propionate are mostly depleted in colonocytes and the liver 
respectively, while acetate, which is produced in the greatest amount, is transported to 
the portal vein and thereafter delivered to peripheral tissues including the brain and 
muscle. Hitherto, little is known on concentrations of gut-derived acetate in the brain, 
let alone its effects on lipid metabolism. Acetate could pass through the blood-brain 
barrier freely (Deelchand et al. 2009). Uptake is almost exclusively by glial cells, 
especially astrocytes because of the expression of monocarboxylate transporter (MCT)-
like protein on their cell membrane (Deelchand et al. 2009). However, despite a high 
rate of uptake, utilisation of acetate by astrocytes is slow. This is thought to be due to 
inactivity of acetyl-CoA synthetase (Luong et al. 2000), supporting findings that acetate 
is not involved in long-chain fatty acid synthesis in brain tissue (Dienel et al. 2001). 
Despite limited metabolic roles in the brain, acetate could potentially participate in 
SCFA-FFAR2 signalling pathways similar to those in the liver. However, there is no 
evidence that FFAR2 is expressed on brain tissue, and little research has assessed the 
possibility of acetate to regulate lipid metabolism through these pathways. 
 
Assessing the functionality of prebiotics 
In light of these complex potential influences of prebiotic metabolites on health, the 
choice of research methods becomes critical to further understanding in this field. In 
many studies focussed on prebiotic effects, emphasis is placed on characterising the 
composition of the gut microbiota (using a range of microbiome analytical techniques) 
to assess the impact of consumption on the resident microbiota (Li et al. 2009; Liu et al. 
2014). However, it is clear that compositional analysis does not provide all the evidence 
needed to demonstrate that a product is a prebiotic. In particular, the intention [Box 1] 
that a prebiotic should be fermented by host microbes and should selectively stimulate 
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the activity of bacteria associated with health and well-being, and thus confer a health 
benefit, would not be answered through assessment of microbial composition alone, but 
would require metabolite analysis (e.g. Edmands et al. 2011). Furthermore, 
incorporation of prebiotics into different matrices such as food products could affect 
beneficial function. Therefore, it is essential that alongside microbial compositional 
analysis, assessment of functionality is complemented by metabolite analysis. Finally, 
the actual health benefit conferred must be measurable, and determined. 
 
Metabolic profiling and short chain fatty acid assessment 
Metabolic profiling could be used to assess the functionality of prebiotics, and better 
understand the impact of dietary supplementation on host health, as it enables 
measurement of bioactive compounds directly in foods and supplements (Kang et al. 
2016), as well as in biological samples. Such data can provide evidence that the 
prebiotic is being fermented by intestinal microbiota, with specific metabolites 
produced and released into the intestinal lumen. For example, SCFA produced following 
fermentation of insoluble dietary fibre by the gut microbiota are released into the 
intestinal lumen to be utilised by other metabolic processes. Metabolic profiling may 
help to identify such products, enabling deeper insights into microbial function. This 
would not account for cross-feeding of metabolites by other microorganisms and, 
depending on the sample, may also miss those absorbed into the body. 
Most studies, especially in humans, have measured SCFA concentrations in faecal 
samples since in vivo measurement is difficult and can be invasive. However, up to 95% 
of the SCFA produced by the microbiota are absorbed (Ruppin et al. 1980) or further 
metabolised by bacterial cross-feeding. Hence, excreted SCFA concentrations, the end-
point of the dynamic metabolism occurring in the gut, provide little information about 
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SCFA production along the colon, particularly in the proximal colon. There are no well-
developed methods to determine SCFA in tissues such as colon, liver, adipose tissue and 
muscles, where they may exert effects in regulating host metabolism. Nonetheless, 
faecal samples are currently the best proxy we have for detecting changes in microbial 
production of SCFA, albeit they depict a balance between production, utilisation and 
absorption. 
Designing a metabolic profiling study to assess prebiotic functionality requires 
careful consideration. There are two main analytical platforms used for metabolic 
profiling: 1H-NMR Spectroscopy and Mass Spectrometry (MS), often hyphenated to 
chromatographic techniques such as Liquid Chromatography (LC-MS) or Gas 
Chromatography (GC-MS) which enable simultaneous capture of hundreds or 
thousands of metabolites from a single sample. The acquired spectral data provide 
information on the presence, absence, and concentration of a metabolite. The choice of 
platform is often dictated by resources (including sample availability and volume) but 
should be driven by the overall hypothesis of a study. Untargeted metabolic profiling 
studies are considered a “top down” systems approach where no prior knowledge is 
applied, in order to capture information relating to multiple mechanisms that are 
associated with a disease class, condition or intervention. Targeted studies, on the other 
hand, focus on detection and quantification of selected molecules or panels of 
metabolites of interest. LC-MS or GC-MS is commonly used for targeted quantification 
since the chromatography enables separation and selection of specific compounds from 
complex mixtures such as human biological samples and the masses of the separated 
compounds are then detected by the MS. This approach has been successfully applied in 
a number of studies to assess functionality (Hornung et al. 2018). As well as choice of 
platform, samples to be analysed in a study will also drive analytical strategy, since 
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different samples can provide various but complementary information. Urine and faecal 
samples mostly contain information on metabolic end products (including those 
produced from bacteria), whereas blood samples (serum and plasma) provide 
information on circulating metabolites that may be absorbed following microbial 
production. In addition to SCFA, there are other compounds present in biological 
samples arising as a result of host-gut microbiota interactions (e.g. branched chain fatty 
acids, bile acids, indoles, cresols, ammonia, gases). Therefore, the study should be 
designed with the optimal analytical strategy, samples and instrumentation, to 
maximise recovery of information.  
Whilst many studies focus on compositional analysis to establish the make-up of 
microbial communities, and how these change in relation to intervention, this does not 
provide a mechanistic understanding of the role of such changes on health and disease 
outcomes. Combining complementary information from microbial and metabolic 
profiling would be one way of addressing this, and several recent studies have 
published results demonstrating the value of data fusion. For example, in a study by 
Vulevic et al. (2015), faecal microbial, immune and metabolic profiles were acquired 
from samples collected from elderly people following a prebiotic (GOS) trial. Analysis of 
bacterial composition revealed an increase in Bacteroides and Bifidobacterium species. 
In this study, bifidobacterial levels were correlated with faecal water metabolic profiles, 
which revealed that higher levels of bifidobacteria were associated with a number of 
metabolites including increased lactate (Vulevic et al. 2015). The authors proposed that 
a potential mechanism for improved health/well-being following prebiotic 
supplementation may be attributed to the anti-pathogenic capability of lactate. 
However, further work is required to validate these findings.   
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State of the evidence, and translation to policy and practice  
Healthcare decisions for individual patients and for public health policies should be 
informed by the best available research evidence. Systematic reviews and meta-
analyses of well conducted randomised controlled trials provide a high level of evidence 
and an unbiased overview of the body of knowledge on a specific topic, which can then 
be used to support the development of clinical practice guidelines. Although interest in 
the field of prebiotics continues to increase, the number of robust randomised trials 
evaluating prebiotic effects on any specific health condition remains limited and thus 
recommendations for their use have not been incorporated into any international 
clinical practice guidelines for the prevention or treatment of a specific disease.  
There is a wealth of candidate prebiotics based on in vitro screening, but far 
fewer human studies clearly demonstrating the functional and clinical benefits to 
confirm prebiotic activity. As we have seen, in vitro screening results may be lost in 
translation when it comes to clinical trials, due to complexity through competitive 
microbes and competitive substrates and inter-individual variation in these factors via 
the microbiome and the diet, respectively. When prebiotic effects do translate to human 
studies, it may be limited to subgroups of responders, in whom dietary, microbiome or 
other individual characteristics create the correct environment.    
Such translational issues make it difficult to reliably select appropriate prebiotics 
for use for clinical end-points. Further variation in expected effects can be introduced 
when the delivery matrix for prebiotic is altered, such as functional foods, resulting in 
sometimes unpredictable changes in activity.   
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When human studies do exist, it is difficult to synthesise data to support 
translation of research findings to the clinical setting (Figure 3). The heterogeneity of 
prebiotics undermines the ability to pool data from different studies testing individual 
prebiotic compounds because different prebiotics will have different effects.  
All of these issues increase the complexity of developing a prebiotic with a 
definitive health benefit. Looking to the future, it is necessary to take a cohesive 
approach to validating the efficacy of a selected prebiotic for use in a specific health 
condition if prebiotics are to be implemented as a prevention or treatment, including 
within the clinical setting.  
 
Prebiotics in the regulatory context 
Japan was the first country in the world to officially regulate functional foods (including 
prebiotic products) with the introduction of Foods for Specified Health Use (FOSHU) act 
in the 1980s. Foods and beverages that claim to provide health benefits to a consumer 
are permitted through the Japanese Ministry of Health, Labour and Welfare, if valid 
scientific proof is provided to support such claims. Foods that are permitted are then 
allowed to be marketed in Japan with FOSHU certification and labelling. Although 
prebiotics are not specifically mentioned, they may be categorised in the ‘Food Related 
to Gastrointestinal Conditions’, where principal ingredients include oligosaccharides, 
lactose, dietary fibre, ingestible dextrin, polydextrose, guar gum, and psyllium seed coat. 
In Europe, the functional food regulation initiative started in Sweden, followed 
by the Netherlands and United Kingdom, later forming Joint Health Claims Initiative 
(JHCI). Subsequently, the European Food Safety Authority (EFSA) was established in 
February 2002. The work of EFSA covers all matters with a direct and/or indirect 
impact on food and feed safety. In addition, EFSA is responsible for verifying the 
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scientific substantiation of health claims, for authorisation in the EU. To date, only one 
prebiotic, chicory inulin, has received an EU health claim by EFSA: ‘Chicory inulin 
contributes to maintenance of normal defaecation by increasing stool frequency’ (EFSA 
NDA Panel, 2015). To obtain the claimed effect, 12 g of native chicory inulin should be 
consumed daily. A second more general health claim relevant to prebiotics states that 
‘non-digestible carbohydrates contribute to a reduction in post-prandial glycaemic 
response’ (EFSA NDA panel 2015). Established prebiotics i.e. fructans and GOS are 
considered as safe food ingredients, while prebiotic ingredients created after 1997 are 
considered novel, thus require safety clearance in the EU within the Novel Food 
Regulation.  
In the USA, the nutritional label and information act was proposed by the Food 
and Drug Authorities (FDA) in 1990 to authorise health claims in food supplements. 
However, prebiotic is not yet a term recognised by the FDA and any microbiota 
modification may not be acceptable as a regulated Health Claim.  
In other parts of the world, prebiotics are often unknown to the end consumer, 
particularly compared to probiotics. In some developing Asian countries, official specific 
regulations regarding prebiotics, and even functional foods or health claims in general, 
are virtually non-existent. This has allowed unregulated food products and supplements 
to become available in the market, with unsubstantiated consumer claims, such as 
health and beauty enhancement. 
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Economic considerations 
Market studies have shown that functional food product sales have increased over the 
last few years (Granato et al. 2010). This demand will keep on changing due to various 
factors such as ageing consumers, increased medical cost, the need and interest of 
individuals to address their health, new scientific discoveries, and amendment of laws 
and regulations regarding food manufacturing. 
To commercialise a prebiotic, many aspects must be considered, including 
functional ingredient determinations, physiological assessments, carrier (food 
matrices) identification, bioavailability studies and consumer acceptance (Kotilainen 
2006). All of these factors need research and input from industries, scientists, 
regulators and consumers. To ensure sustainability of a prebiotic, the product also 
needs to meet the demand of consumers by fulfilling stated claims in the final purchased 
product, not the ingredient. 
 
One interesting economic strategy is to assess prebiotic sources in agricultural 
by-product surplus i.e. ‘waste to wealth’. Growth in human populations increases food 
demand, and thus agricultural expansion. This leads to increases in quantities of 
livestock waste, agricultural crop residues and agro-industrial by-products. Crop 
biomass from agricultural waste such lignocellulose or non-starch polysaccharide, 
contains three major polymer groups i.e. cellulose, hemicellulose and lignin, which can 
be potential prebiotic sources for sustainable agricultural practice. These components 
can be converted to useful prebiotic oligosaccharides using various non-starch 
polysaccharide-degrading enzymes, e.g. cellulase, hemicellulase, xylanase, pectinase, β-
glucanase and α-galactosidase. Such products could have important uses in human 
health but also in animal husbandry, particularly in the current era of promoting animal 
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growth and maintaining health while minimising the use of antimicrobials. The role of 
non-starch polysaccharides in fish nutrition has been reviewed previously (Kumar et al. 
2011). 
 
An Asian perspective 
The ISAPP meeting hosting this discussion group took place in Singapore, hence one of 
the considerations of future prebiotic potential was within Asia. To date, the largest 
consumers of health food or nutraceuticals are in the Asian Pacific, particularly Japan. 
Japan is a significant market, as about 1700 functional food products (including 
prebiotics) have been validated with the FOSHU label since 1991. The sales (per capita) 
of functional food in Japan is consistently the largest in the world (Sumio and Jharrod 
2014). This may in turn benefit industry by encouraging continuous investment in 
research and development.  
Despite other Asian countries not being familiar with the term prebiotic (apart 
from its use in infant formulae), the demand for food supplements containing prebiotics 
has increased over recent years. One interesting market is South Korea, where 
consumers may prefer functional foods that could enhance beauty and aesthetic issues. 
South East Asian countries particularly Malaysia, Thailand and the Philippines are also 
significant markets for functional foods. Many prebiotic ingredients that are exported, 
mostly from Europe, are incorporated into supplements like health drinks, powdered 
fibre shots, chewable candies and spray-dried milk. Some are also locally produced 
using traditional preparations. Without doubt, the prebiotic industry in Asia is gaining 
momentum. This development may enhance global markets and international 
cooperation in prebiotic science via technology transfer, hopefully to benefit many more 
consumers. One concern for global markets is the exploitation of unregulated countries, 
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and consumer ignorance solely for the advantage of suppliers and manufacturers. 
Standardised regulations for prebiotics are an essential way forward.   
 
Conclusion 
Our understanding of prebiotics has evolved significantly over the past 20 years, with 
these compounds now understood to exert complex effects on the gut microbiota 
composition and function. Despite an increase in understanding, the list of validated 
prebiotics (with in vivo evidence) remains limited. While there is a range of promising 
prebiotic candidates from in vitro studies, few have the appropriate intervention studies 
which demonstrate selective microbiome fermentation and measurable health benefits 
to enable them to meet the requirements of a prebiotic. With the vast majority of 
research remaining focussed on the gastrointestinal tract, and indeed the large 
intestine, it is clear that there are opportunities for the development of prebiotics 
targeted towards other host microbial ecosystems. 
Increasing complexity in confounding microbiome and dietary factors hinder the 
translation of in vitro studies to in vivo studies, and inter-individual variation results in 
responders and non-responders. Assessing functionality using analytical chemistry 
approaches such as metabolic profiling, shows promise in supporting researchers in 
understanding the mechanisms by which prebiotics can improve health and well-being 
on an individual basis. Integration of complementary datasets (e.g. microbial and 
metabolic) aids in building a holistic picture to fully understand the contribution of 
prebiotics and the gut microbiota in shaping host health outcomes and may enable 
better prediction of health benefits and design of optimal prebiotic interventions. 
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The delivery of prebiotics in multiple formats, ranging from whole foods, 
functional foods and supplements provides unique advantages for particular 
individuals. However, for both the researcher and the consumer, it is important to note 
that differences in therapeutic impact have been observed between different delivery 
formats, highlighting the importance of trials of the final product, in the intended 
population. While new trials for each new format are not always possible due to 
practical and economic considerations, further mechanistic understanding of the impact 
of food matrix on prebiotic function in vivo is warranted.  
New prebiotic candidates from non-Western geographical regions and alternate 
channels such as agricultural waste may offer promise in the future for novel prebiotics 
with unique health benefits and positive social, economic and environmental impact 
profiles. Compounds beyond the current prebiotic carbohydrates, such as polyphenols, 
may also provide the next generation of prebiotics. The ultimate challenge remains in 
linking changes in microbial composition, activity and metabolic output with a 
measurable health benefit.  
 
Advances in the above areas can create a broader range of prebiotics with a 
sophisticated understanding of their potential to provide health benefits to a global 
audience.  
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Table 1 (adapted from Joshi et al. 2018) 
Confirmed prebiotics    Food Source  
                                                                                                     Content of specific prebiotic fibre (%) 
Galacto-oligosaccharides (GOS)    β-GOS produced enzymatically from lactose 
 
Fructo-oligosaccharides (FOS)   Asparagus (5%), leeks (11.7%), garlic (17.5%),  
Inulin  chicory (64.4%), onion (8.6%), Jerusalem artichoke 
(31.5%), wheat (2%), banana (1%) 
Lactulose     synthetic disaccharide 
 Candidate prebiotics 
Soy, Soybean oligosaccharides   Soybeans (2.3 stachyose, 7 raffinose) 
Pectin      cell wall component of many fruits 
Cellulose     General component of plant cell walls 
Resistant starch     Multiple food sources (corn, potato, tapioca, etc.) 
Xylan, Xylooligosaccharides,    Wheat bran 
Arabinoxylooligosaccharides  
Mannose     many fruits and vegetables 
Maltose, Maltooligosaccharides   breakdown products from starch 
 
Isomaltulose     Honey, sugarcane juice, sucrose 
Palatinose     patented form of isomaltulose, made from beet 
sugar  
Polydextrose     synthetic fibre 
Raffinose oligosaccharides Lentils (0.16%), peas (0.5%), beans (0.33%),  
 chickpeas (0.4%) 
β-glucans     soluble fibre found in oats and barley cereals (3-6%) 
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Figure legends 
Box 1 Definition and required criteria for prebiotic classification 
 
Figure 1 Considerations for choice of prebiotic formats 
Prebiotics may be delivered in a variety of formats, including isolated prebiotic 
compounds as supplements, the incorporation of these compounds into processed 
foods, or the consumption of whole food natural sources of prebiotics. The choice of 
delivery format for prebiotics depends on a variety of factors intrinsic to the prebiotic 
product as well as the end consumer. 
 
Figure 2 Key functions of prebiotics 
Prebiotics enter the host gut and are acted on by the microbiota, impacting the 
microbiota composition and function, and stimulating significant changes in metabolite 
production (chiefly short chain fatty acids). These changes within the host create a 
range of potential biochemical and physiological alterations and local and systemic 
health benefits.  
 
Figure 3 Translation and clinical effects of prebiotics 
In vitro prebiotic screening (a) creates data on observed growth patterns of specific 
organisms when exposed to specific prebiotics under controlled environments. More 
complex screening models (b) such as co-cultures and gut simulators may expand this 
screening to encompass multiple organisms and multiple substrates, to capture 
bacterial and substrate interactions. These growth effects do not always translate to 
human studies (c), where the complex interactions of many species and many dietary 
compounds create a complicated and unpredictable web of interactions. When results 
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from human studies are used to guide clinical prescribing (d), effects do not always 
occur reliably in each individual due in large to dietary and microbiome differences, as 
well as inter-individual variations in preferences and compliance. 
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